Next Article in Journal
Triazole Fungicide Residues and Their Inhibitory Effect on Some Trichothecenes Mycotoxin Excretion in Wheat Grains
Next Article in Special Issue
Synergizing Off-Target Predictions for In Silico Insights of CENH3 Knockout in Cannabis through CRISPR/Cas
Previous Article in Journal
Improved Diazo-Transfer Reaction for DNA-Encoded Chemistry and Its Potential Application for Macrocyclic DEL-Libraries
Previous Article in Special Issue
Impact of Matrix Metalloproteinase-9 during Periodontitis and Cardiovascular Diseases
Article

A Novel Dual Drug Approach That Combines Ivermectin and Dihydromyricetin (DHM) to Reduce Alcohol Drinking and Preference in Mice

1
Titus Family Department of Clinical Pharmacy, University of Southern California School of Pharmacy, Los Angeles, CA 90089, USA
2
Molecular Design and Synthesis Group, Rutgers University Biomedical Research Innovation Core, Piscataway, NJ 08854, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Ana Paula Duarte, Ângelo Luís, Eugenia Gallardo and Masahide Hamaguchi
Received: 28 January 2021 / Revised: 18 March 2021 / Accepted: 19 March 2021 / Published: 22 March 2021
(This article belongs to the Special Issue Natural Products: Therapeutic Properties and Beyond)
Alcohol use disorder (AUD) affects over 18 million people in the US. Unfortunately, pharmacotherapies available for AUD have limited clinical success and are under prescribed. Previously, we established that avermectin compounds (ivermectin [IVM] and moxidectin) reduce alcohol (ethanol/EtOH) consumption in mice, but these effects are limited by P-glycoprotein (Pgp/ABCB1) efflux. The current study tested the hypothesis that dihydromyricetin (DHM), a natural product suggested to inhibit Pgp, will enhance IVM potency as measured by changes in EtOH consumption. Using a within-subjects study design and two-bottle choice study, we tested the combination of DHM (10 mg/kg; i.p.) and IVM (0.5–2.5 mg/kg; i.p.) on EtOH intake and preference in male and female C57BL/6J mice. We also conducted molecular modeling studies of DHM with the nucleotide-binding domain of human Pgp that identified key binding residues associated with Pgp inhibition. We found that DHM increased the potency of IVM in reducing EtOH consumption, resulting in significant effects at the 1.0 mg/kg dose. This combination supports our hypothesis that inhibiting Pgp improves the potency of IVM in reducing EtOH consumption. Collectively, we demonstrate the feasibility of this novel combinatorial approach in reducing EtOH consumption and illustrate the utility of DHM in a novel combinatorial approach. View Full-Text
Keywords: dihydromyricetin; flavonoids; alcohol; alcohol use disorder; ivermectin dihydromyricetin; flavonoids; alcohol; alcohol use disorder; ivermectin
Show Figures

Figure 1

MDPI and ACS Style

Silva, J.; Carry, E.; Xue, C.; Zhang, J.; Liang, J.; Roberge, J.Y.; Davies, D.L. A Novel Dual Drug Approach That Combines Ivermectin and Dihydromyricetin (DHM) to Reduce Alcohol Drinking and Preference in Mice. Molecules 2021, 26, 1791. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26061791

AMA Style

Silva J, Carry E, Xue C, Zhang J, Liang J, Roberge JY, Davies DL. A Novel Dual Drug Approach That Combines Ivermectin and Dihydromyricetin (DHM) to Reduce Alcohol Drinking and Preference in Mice. Molecules. 2021; 26(6):1791. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26061791

Chicago/Turabian Style

Silva, Joshua, Eileen Carry, Chen Xue, Jifeng Zhang, Jing Liang, Jacques Y. Roberge, and Daryl L. Davies 2021. "A Novel Dual Drug Approach That Combines Ivermectin and Dihydromyricetin (DHM) to Reduce Alcohol Drinking and Preference in Mice" Molecules 26, no. 6: 1791. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26061791

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop